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In this issue, Alvin King, Daniele Piomelli, and colleagues publish another interesting paper on inhi-
bition of monoacylglycerol lipase (MGL). MGL is a hot target for antinociceptive agents, being the
chief degrading enzyme of the endocannabinoid 2-arachidonoylglycerol [1].‘‘The problem of pain’’ [2] has troubled
everybody, often to the verge of
despair. Equally troublesome and de-
spairing have been efforts at develop-
ing analgesics. Pathwayswere discov-
ered that simply must have something
to do with sensing, transmitting, and
realizing pain, and inhibitors were
found that worked ever so well in the
usual animal models of antinocicep-
tion—but in humans, they apparently
failed to cause or display distinct ef-
fects. In humans at least, pain is
a very subjective state of perception,
and that is probably why linear extrap-
olations from molecular to clinical
effects are rarely possible. Perhaps
the same biochemical events will be
interpreted differently by the mind
when it comes to states of conscious-
ness like pain? To, as it were, chemi-
cally detach a patient from feeling his
pain, without impairing his emotional
and intellectual capacities, remains
a major challenge with very likely no
satisfactory solution.
Listing all known molecular targets
of approved drugs [3], we identified
eight whose stimulation or blockade
are thought to lead to analgesia or anti-
nociception, not counting the targets
of neuroleptics and tranquilizers thathave an analgetic by-effect. Against
this background, new molecular tar-
gets that hold the promise of being
relevant for nociception are always
welcome. In this context, nociception
or hyperalgesia means that even slight
touches or pressures (e.g., caused
by swellings or inflammation) induce
pain, as opposed to pain caused by
a fracture or hard blow. The endocan-
nabinoid—or rather eicosanoid—sys-
tem that has been discovered during
the past years is strongly involved in
basic sensory physiology including
nociception.
Presently, the endocannabinoid sys-
tem [4, 5] is known to consist mainly of:
(1) two receptors of the G protein cou-
pled receptor family, CB1 and CB2; (2)
endogeneous ligands that are derived
from arachidonic acid, like ananda-
mide and 2-arachidonoyl glycerol
(2-AG); (3) a transporter of anandamide
that has escaped thorough character-
ization so far; and (4) hydrolases that
catalyze the biosynthesis and inactiva-
tion of the ligands. 2-AG is inactivated
by two or more monoacylglycerol
lipases (MGL, MAGL), while ananda-
mide is hydrolyzed by fatty-acid amide
hydrolase (FAAH) and N-acylethanol-
amine acid amidase (NAAA).Chemistry & Biology 14, December 2007 ªCB receptors are supposed to be
more numerous in the CNS than dopa-
mine receptors, and they were also
found in other body tissues. Endocan-
nabinoid signaling, which is of the
short-range short-term type, is strongly
involved in antinociception, anxiolytic
action, cell proliferation, reproduction,
memory processes, and modulation of
feeding [3].
Due to its abuse, it has long been
known that cannabis has analgesic
effects. At the moment, the following
modulators of the endocannabinoid
system are thought to lead to analge-
sic action: agonists at CB1 and/or
CB2 receptors, inhibitors of FAAH,
and inhibitors of MGL. The latter two
interferences would work indirectly by
increasing the amount of endocanna-
binoids.
Cause-and-effect is anything but
clear with endocannabinoids. Different
literature reports have shown, for in-
stance, the CB2 receptor and 2-AG
to be strongly involved in stimulation
and in attenuation of inflammation
and immune responses [6]. Apart from
the consideration on nondetermined-
ness of psychopharmaceutical ac-
tion, the intertwining of the CB and
other pathways need to be taken2007 Elsevier Ltd All rights reserved 1311
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PreviewsFigure 1. A Few Endogeneous and Synthetic Players of the Endocannabinoid System
and a Few Hints at the Extensive Connectivity of the Arachidonatesinto account (Figure 1). Receptors and
enzymes should be likened to switch-
boards rather than switches, or to
junctions rather than stops of a path-
way. Blocking MGL or FAAH will, for
instance, deplete the cyclooxygenase
isoenzymes of some of their substrate,
leading to the diminished production
of prostaglandins, leukotriens, hydrox-
yperoxyacids, and other eicosanoids.
Anandamide has also been shown to
act agonistically at the vanilloid recep-
tor, an ion channel now known as
TRPV1 [7]. Whether this is of quantita-
tive importance remains to be investi-
gated; however, it highlights two of
many biochemical ‘‘ripples’’ away from
the simple increase of 2-AG levels
through MGL inhibition.
FAAH inhibition has been studied
much more intensively than MGL inhi-
bition because MGL was character-
ized later than FAAH and because spe-
cific inhibitors of MGL were harder to
find.MGLwas found in 1976 [8], cloned
in 1997 [9], and is considered as the
main enzyme catalyzing the hydrolysis
of 2-AG. In rats it was shown to be
ubiquitous [7], in rat brain it is mainly
present in axons, and in the amygdala
MGL is localized presynaptically [10].
In 2007, the MGL inhibitor URB602
(biphenyl-3-ylcarbamic acid cyclo-
hexyl ester) was shown to induce anti-
nociception in the mouse paw and
enhance the antinociceptive effects
of exogenously applied 2-AG, thereby1312 Chemistry & Biology 14, Decemberdemonstrating the efficacy of an MGL
inhibitor in suppressing inflammatory
nociception [11]. The effect seems to
be due to CB2 stimulation [12].
In this issue, King et al. [1] investi-
gated two inhibitors of cytosolic MGL,
viz. URB602 and MAFP (methylarachi-
donylfluorophosphonate). Both were
previously shown to lead to elevated
2-AG levels and enhanced 2-AG-me-
diated signaling in neurons [13, 14].
However, reports on the details of the
action and mechanism of URB602
and MAFP are not unequivocal, and
MGL awaits thorough validation as
a therapeutic target. The results of
King et al. take us a step forward in
showing that URB602 indeed does
lead to elevated 2-AG levels in rat
brain. With an IC50 of220 mM against
recombinant MGL, URB602 is not ef-
fective enough to qualify as a drug,
but as King et al. also showed that it
is a noncovalent inhibitor, the N-aryl-
carbamate scaffold of URB602 makes
it an attractive starting point for fur-
ther pharmaceutical chemical devel-
opment. The evidence that it inhibits
MGL noncompetitively, however, adds
a note of caution since target organ-
isms can easier evade noncompetitive
inhibitors by increasing the expression
of or developing a nonbinding active
mutation than to deal with competitive
inhibitors.
Nonetheless, with previous work
that provided some proof of concept2007 ª2007 Elsevier Ltd All rights reservedfor MGL inhibition in antihyperalgesia,
the current work by King et al. that
clarified mechanistic details, and with
the discovery of another, more potent
carbamate inhibitor of MGL (SPB
01403, n-butylcarbamic acid 4-(4,5-di-
hydrothiazol-2-yl)phenyl ester) [15], a
hopeful new road to analgesic agents
is wide open. It will involve keeping
a reserve of the right fatty acid deriva-
tives to soothe the pain. So, we better
let our fat do its pharmacological work
rather than consider it just a burden.
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